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Central chemoreﬂexWe evaluated the effects of parasympathetic activation by pyridostigmine (PYR) on chemoreﬂex sensitivity in a
rat model of heart failure (HF rats). HF rats demonstrated higher pulmonary ventilation (PV), which was not af-
fected by PYR. When HF and control rats treated or untreated with PYR were exposed to 15% O2, all groups
exhibited prompt increases in respiratory frequency (RF), tidal volume (TV) and PV.WhenHF ratswere exposed
to 10%O2 they showed greater PV responsewhichwas prevented by PYR. The hypercapnia triggered by either 5%
CO2 or 10% CO2 promoted greater RF and PV responses in HF rats. PYR blunted the RF response in HF rats but did
not affect the PV response. In conclusion, PYR prevented increased peripheral chemoreﬂex sensitivity, partially
blunted central chemoreﬂex sensitivity and did not affect basal PV in HF rats.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Sympathetic overactivity (Liu and Zucker, 1999; Zucker, 2006;
Schultz and Li, 2007; Zucker et al., 2012) and reduced vagal drive to
the heart (Bibevski and Dunlap, 1999, 2011) are hallmarks of heart fail-
ure (HF) at the clinical and experimental levels. This cardiac autonomic
imbalance is related to an increase in central sympathetic outﬂow in-
volving central neurotransmitters as nitric oxide and angiotensin II
(Zucker and Liu, 2000) and to abnormalities in the cardiorespiratory re-
ﬂexes, including attenuation of the baroreﬂex and the cardiopulmonary
reﬂex, which are sympatho-inhibitory reﬂexes (Wang et al., 1991;
Mancia et al., 1992). Further changes in autonomic control involve an
increase in the sympatho-excitatory reﬂexes, including the chemoreﬂex
and the cardiac sympathetic afferent reﬂexes (Zhu et al., 2002; Schultz
and Li, 2007; Zucker et al., 2012). Peripheral arterial chemoreceptors
are situated in the carotid sinus and aortic arch (Chugh et al., 1996)
while central chemoreceptors are located on the ventral surface of the
medulla (Schultz and Sun, 2000). The peripheral chemoreﬂex is stimu-
lated by decreased fractional inspired O2 (Guyenet, 2000), while the
increased fractional inspired CO2 triggers both the central and the pe-
ripheral chemoreceptor activity (Lahiri and Forster, 2003; Blain et al.,
2010). Our laboratory has previously demonstrated that hypercapnia
induced by 10% of CO2 in inspired air elicits a hyperventilation thatSchool of Medicine of Ribeirão
, SP, Brazil. Tel.: +55 16 3602
rights reserved.does not involve peripheral chemoreceptors in conscious rats (Sabino
et al., 2013b).
Heart failure leads to an increase in peripheral chemoreﬂex sensitiv-
ity and has been well-documented in rats (Reddy et al., 2007; Wang et
al., 2008), rabbits (Sun et al., 1999; Ding et al., 2011) and patients (Chua
et al., 1996; Ponikowski et al., 2001). In addition, Ponikowski et al.
(2001) have shown that augmented peripheral chemoreﬂex sensitivity
is an independent predictor of mortality in HF patients. Likewise, previ-
ous studies have shown enhanced central chemoreﬂex sensitivity in HF
patients (Narkiewicz et al., 1999;Ueno et al., 2004; Yamada et al., 2004).
However, experimental studies have demonstrated that HF does not
alter the central chemoreﬂex sensitivity of rabbits (Sun et al., 1999)
and anesthetized rats (Kristen et al., 2002).
Sympathetic hyperactivity has been thoroughly investigated in HF
(Liu and Zucker, 1999; Zucker, 2006; Schultz and Li, 2007), and phar-
macological approaches targeting the cardiac sympathetic drive are
being developed to treat this disease (Bibevski and Dunlap, 2011).
However, the reduced cardiac vagal tone in HF has not received the
same attention. Nevertheless, recent studies have demonstrated that
vagal stimulation prevents pump failure (De Ferrari et al., 2011) and
inhibits HF-related cardiac remodeling and arrhythmias, improving
long-term survival in animals with chronic HF (Li et al., 2004;
Zheng et al., 2005; Zhang et al., 2009). Therefore, an increase in para-
sympathetic function may be an alternative therapeutic approach
preventing at least a fraction of the outcomes of HF.
Chemoreﬂex sensitivity is impairedby electrical stimulation of thedis-
tal cut end of glossopharyngeal and/or carotid sinus nerves in normal an-
imals (Eyzaguirre and Koyano, 1965; Fidone and Sato, 1970; Campanucci
and Nurse, 2007), demonstrating the inﬂuence of parasympathetic drive
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stimulation on the enhanced chemoreﬂex sensitivity in situations such
as HF has not been investigated.
Pyridostigmine bromide (PYR) promotes increase of parasympathetic
neurotransmission by inhibiting, peripherally, the enzymatic breakdown
of acetylcholine at cholinergic receptor sites (Taylor, 2001; Androne et
al., 2003). Moreover, PYR treatment shows indirect signals of enhanced
parasympathetic activity, such as bradycardia and higher HR variability
in rats (Soares et al., 2004), healthy humans (Nobrega et al., 2001), and
patients with HF (Behling et al., 2003).
Our laboratory has demonstrated a protective effect of PYR on cardiac
autonomic control, systolic arterial pressure variability and baroreﬂex
sensitivity, due to an increase in parasympathetic function, 6–7 weeks
after the onset of HF in rats (Sabino et al., 2013a). However, to the best
of our knowledge, no study has investigated the effect of PYR on the
well-documented enhanced peripheral and central chemoreﬂex sensi-
tivity observed in HF.
Therefore, the aim of the current study was to evaluate in HF rats
the effect of pharmacological activation of parasympathetic function
by PYR on the peripheral chemoreﬂex by examining the respiratory
responses to hypoxia and to elucidate the effect of PYR on the central
chemoreﬂex by examining the respiratory responses to hypercapnia.
In addition, the current study examines in HF rats the effect of PYR on
baseline mean arterial pressure (MAP), heart rate (HR), respiratory
frequency (RF), tidal volume (TV), pulmonary ventilation (PV) and
cardiac function.
2. Methods
Experiments were performed on male Wistar rats (280 to 300 g)
housed individually with free access to food and water and maintained
on a 12:12 h light–dark cycle. All experimental procedures were carried
out in accordancewith theGuide for the Care andUse of Laboratory Animals
[Dept. of Health, Education andWelfare, Publication No. (NIH) 85-23, Re-
vised 1985; Ofﬁce of Science and Health Reports, DRR/NIH, Bethesda,
MD]. The experimental protocols were approved by the Committee of
Ethics in Animal Research of the School of Medicine of Ribeirão Preto,
University of São Paulo (protocol 151/2010).
2.1. Surgical procedures
Six to seven weeks before the experiments, the animals were anes-
thetized with a mixture of ketamine (50 mg/kg, ip União Química
Farmacêutica Nacional S/A, Embu-Guaçu, SP, Brazil) and xylazine
(10 mg/kg, ip Hertape Calier Saúde Animal S/A, Juatuba, MG, Brazil)
and were endotracheally intubated and mechanically ventilated with
a respirator (Harvard Apparatus Rodent Respirator, Model 680,
Holliston, MA, USA). Heart failure was produced by coronary artery
ligation as previously described by Pfeffer et al. (1979). Brieﬂy, a left
thoracotomy was performed through the ﬁfth intercostal space, the
pericardiumwas opened and the heart was externalized. The left ante-
rior descending coronary artery was subsequently ligated with polyes-
ter suture (4-0: Ethicon, São José dos Campos, SP, Brazil). The heart was
brought back to the thoracic cavity, and the incisionwas sutured closed.
The infarct size was conﬁrmed by post-mortem examination, and only
rats with infarct size N40% of the left ventricular wall were used in
the study. Sham-operated control rats underwent a similar surgical
procedure without coronary ligation. At the end of the surgery, the an-
imals received analgesic (ﬂunixin meglumine, 2.5 mg/kg, sc) and were
maintained in the animal care facility of the Department of Physiology
at the School of Medicine of Ribeirão Preto. For three days following
the surgical procedure, the animals were treated with analgesic daily
(ﬂunixin meglumine, 2.5 mg/kg, sc). The animals were subsequently
housed for six to seven weeks until data collection. During this period,
they received pure water or PYR (Valeant Farmacêutica do Brasil Ltda,
Campinas, SP, Brazil) dissolved in drinking water (0.14 mg/mL). Theconsumption of water ranged from 53 to 55 mL/rat/day and did not
differ among groups. Therefore, the dose of PYR was approximately
22 mg/kg/day in either Sham-operated or infarcted rats. This dose of
PYR was based on a previous study by our laboratory (Sabino et al.,
2013a). Two days before the experiments, the rats were anesthetized
with a mixture of ketamine (50 mg/kg, ip União Química Farmacêutica
Nacional S/A, Embu-Guaçu, SP, Brazil) and xylazine (10 mg/kg, ip
Hertape Calier Saúde Animal S/A, Juatuba,MG, Brazil) and instrumented
with polyethylene catheters into the femoral artery for direct measure-
ment of arterial pressure (AP). The catheters were tunneled subcutane-
ously and exteriorized in the nape of the neck, and the surgical incision
sites were sutured. The animals were allowed to recover in individual
cages until the end of the experimental protocol.
2.2. Measurement of arterial pressure
The arterial catheter was connected to a pressure transducer
(MLT0380/D, ADInstruments, Sydney, Australia), and the AP signal
was ampliﬁed (ML110, ADInstruments, Sydney, Australia), fed to an
IBM/PC connected to a Power Lab (ML866, ADInstruments, Sydney,
Australia) and continuously sampled (2 kHz). MAP and HR were
calculated from the pulsatile arterial pressure.
2.3. Measurement of respiratory parameters
Respiration was studied by unrestrained whole-body plethysmogra-
phy (Bartlett and Tenney, 1970) at ambient barometric pressure and at
a temperature that matched body core temperature saturated with
water vapor (BTPS). The rats were placed into a 5 L Plexiglas chamber
(with exit ports for catheters), which allowed them to move freely. Vari-
ous gas mixtures were allowed to easily pass through the chamber to
change the gas concentration. The gas concentration inside the chamber
was continuouslymonitored by anO2 analyzer (GasAlertMaxXT, Canada)
and a CO2 analyzer (microCapStar CO2 Monitor, PA, USA). The chamber
was sealed, except for the inlet and outlet ports that allowed continuous
ﬂow of air. A ﬂowmeter gas mixing pump (Cameron, Canada) allowed
the injection of various gas concentrations into the chamber. To measure
the respiratory parameters, airﬂow through the chamberwas interrupted
for a short time (1 min), and the inlet and outlet ports were sealed. Pres-
sure oscillations causedby respiratorymovementsweredetectedby adif-
ferential pressure transducer (ML141, ADInstruments, Sydney, Australia)
and were digitally recorded in an IBM/PC connected to a PowerLab
System (ML866, ADInstruments, Sydney, Australia). Volume calibration
was achieved during each measurement by injecting a known volume
(1 mL) of air into the chamber. Tidal volume (TV) was calculated ofﬂine
using the formula described by Bartlett and Tenney (1970). Respiratory
frequency (RF) was calculated from the excursion of the TV signal using
an average cyclic rate built into the computer software LabChart v7.2
(ADInstruments, Sydney, Australia). Pulmonary ventilation (PV) was
calculated as the product of TV and RF.
2.4. Experimental protocol
The experimental protocol was adapted from a previous study in
our laboratory (Sabino et al., 2013b). Each animal was individually
placed into the plethysmographic chamber at 25 °C and was allowed
to move freely while the chamber was ﬂushed with humidiﬁed air
(21% O2, 79% N2, 1.2 L/min) for 40–50 min, which allowed for accli-
matization. After the measurement of baseline respiratory parame-
ters and arterial pressure, each animal was submitted to 2 levels of
hypoxia (15% O2 and 10% O2) and 2 levels of combined hypercapnia
and hyperoxia (5% CO2 + 26% O2 and 10% CO2 + 31% O2). The
order of each episode of hypoxia and hypercapnia was chosen ran-
domly, and episodes were spaced 20 min apart.
Hypoxia was achieved by ﬂushing 100% N2 through the chamber.
Nitrogen ﬂow was adjusted to 1.6 or 3.5 L/min to achieve 15% O2 or
Table 1
Characteristics from heart failure rats and sham-operated control rats.
Control Heart failure
Water
(n = 11)
PYR
(n = 8)
Water
(n = 7)
PYR
(n = 7)
BW (kg) 0.565 ± 0.01 0.566 ± 0.02 0.567 ± 0.01 0.530 ± 0.01
Heart (g) 1.34 ± 0.06 1.34 ± 0.02 2.00 ± 0.05⁎ 2.00 ± 0.05⁎
Heart/BW (g/kg) 2.37 ± 0.04 2.29 ± 0.04 3.64 ± 0.06⁎ 3.74 ± 0.05⁎
Lung (g) 1.38 ± 0.08 1.25 ± 0.06 1.86 ± 0.06⁎ 1.89 ± 0.09⁎
Lung/BW (g/kg) 2.45 ± 0.13 2.23 ± 0.10 3.31 ± 0.06⁎ 3.57 ± 0.17⁎
IS (%) – – 50.2 ± 1.4⁎ 48.9 ± 1.9⁎
BW: body weight; IS: infarct size; PYR: pyridostigmine.
⁎ P b 0.05 compared to sham-operated control rats.
Table 2
Basal hemodynamics and respiratory parameters fromheart failure rats and sham-operated
control rats.
Control Heart failure
Water (n = 10) PYR (n = 7) Water (n = 7) PYR (n = 7)
MAP (mm Hg) 111 ± 1 113 ± 3 100 ± 3⁎ 97 ± 3⁎
HR (bpm) 325 ± 10 303 ± 12 307 ± 7 310 ± 7
Water (n = 11) PYR (n = 8) Water (n = 7) PYR (n = 7)
RF (cycles/min) 105 ± 6 121 ± 5 128 ± 9 122 ± 10
TV (mL/kg) 4.5 ± 0.2 4.5 ± 0.3 5.1 ± 0.2 4.7 ± 0.3
PV (mL/kg/min) 480 ± 46 541 ± 43 652 ± 31⁎ 568 ± 59
MAP: mean arterial pressure; HR: heart rate; RF: respiratory frequency; TV: tidal
volume; PV: pulmonary ventilation; PYR: pyridostigmine.
⁎ P b 0.05 compared to sham-operated rats.
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at either 5% CO2 + 26% O2 or 10% CO2 + 31% O2 was also achieved
within 45 s by ﬂushing the chamber with 50% CO2 and 50% O2 at
1.1 or 1.8 L/min, respectively. Each period of chemoreceptor stimula-
tion was maintained for 1 min, while the respiratory parameters
were measured. The chamber was then immediately opened to atmo-
spheric air, and the animals were allowed to recover for 20 min. The
following day, the rats were anesthetized with sodium pentobarbital
(40 mg/kg ip, Rhobifarma Indústria Farmacêutica Ltda, Hortolândia,
SP, Brazil), and a Mikro-Tip pressure catheter (SPR-407, Millar Instru-
ments; Houston, TX, USA) was inserted into the right carotid artery
and advanced into the left ventricle (LV) as described elsewhere
(Pacher et al., 2008). After stabilization of hemodynamic parameters,
the ventricular pressure was recorded by an IBM/PC attached to an
analogic-to-digital interface (PowerLab/4SP, ADInstruments, Mountain
View, CA, USA). The LV end-diastolic pressure (LVEDP), maximal slope
of systolic pressure increment (+dP/dt_max) and diastolic pressure
decrement (−dP/dt_max) were calculated using the built-in blood
pressure module of the LabChart v7.2 software (ADInstruments, Moun-
tain View, CA, USA). After the recordings were obtained, the heart and
lungs were rapidly removed under anesthesia. The organs were subse-
quently rinsed in ice-cold 0.9% NaCl solution and weighed. The heart
ventricles were cut transversely into two parts to be used for infarct
analysis. Cardiac hypertrophy was evaluated by cardiac weight index
(heartweight/bodyweight ratio), and pulmonary edemawas evaluated
by lung weight index (lung weight/body weight ratio).
2.5. Morphological analysis
After transversely cutting the heart, the section containing the
apex was ﬁxed in phosphate-buffered 10% formalin and stained
with picrosirius red (to assess infarct size). The remaining heart sec-
tion was ﬁxed in phosphate-buffered 10% formalin and submitted to
parafﬁn inclusion. Each block was cut into 7-μm serial sections begin-
ning at the midventricular surface. The sections were stained with
picrosirius red for the analysis of the infarct size. The thickness of
the left ventricular wall and the infarct size were measured using
the public-domain software NIH Image J (developed by U.S. National
Institutes of Health and available on the site http://rsb.info.nih.gov/
nih-image). The infarct size was calculated by dividing the length of
infarcted area by the total circumference of the LV and was expressed
as a percentage.
2.6. Statistical analysis
The results are expressed as the mean ± standard error of the
mean (SEM). The basal values (MAP, HR, RF, TV and PV) and changes
in response to hypoxia and hypercapnia (ΔRF, ΔTV and ΔPV) were
evaluated using two-way ANOVA followed by the Tukey post-test.
Differences were considered statistically signiﬁcant for P b 0.05.
3. Results
3.1. Animal characteristics
Body weight was similar among groups, while heart and lung
weight indices were higher in HF rats compared to sham-operated
control rats (Table 1). Infarcted areas were similar between HF rats
treated with PYR and HF rats given water alone (Table 1).
3.2. Basal hemodynamics, respiratory parameters and cardiac function
HF rats treated with PYR or water alone exhibited lower MAP but
similar HR compared to their sham-operated counterparts (Table 2).
Baseline values of RF and TV were not statistically different among
groups. PV was higher in HF rats treated with water but was normalin HF rats treated with PYR compared to sham-operated rats treated
or untreated with PYR. HF led to lower +dP/dtmax and −dP/dtmax
and higher LVEDP, and PYR did not affect these parameters (Table 3).
3.3. Respiratory responses to various levels of hypoxia and hypercapnia
Hypoxia at either 15% O2 or 10% O2 elicited a prompt and marked
rise in RF, TV and PV (Fig. 1). Nevertheless, the respiratory responses
to hypoxia at 15% O2 were similar in sham-operated and HF rats treated
or untreated with PYR. Increases in RF and TV with a stronger hypoxic
stimulus (10% O2) were similar in all groups studied. Nevertheless, PV
(the product of RF and TV) was higher in HF rats treated with water
compared to sham-operated control rats, and PYR prevented this in-
crease (Fig. 1).
Changes in respiratory parameters elicited by the two levels of hy-
percapnia are shown in Fig. 2. Hypercapnia due to either 5% CO2 or
10% CO2 caused a prompt and marked increase in all respiratory pa-
rameters (Fig. 2). HF rats demonstrated a greater RF response than
sham-operated control rats exposed to either 5% CO2 or 10% CO2.
PYR prevented this increased response in HF rats (Fig. 2). The increase
in TV elicited by hypercapnia was similar among all groups. PV in-
creased more in HF rats, and PYR did not change this response.
4. Discussion
Thepurpose of the current studywas to evaluate the effect of PYR, an
acetylcholinesterase inhibitor, on peripheral and central chemoreﬂex
sensitivity six to seven weeks after the onset of HF in rats. Physiological
stimulus, i.e. rapid changes in inspired concentration of O2 and/or CO2,
was used to evaluate chemoreﬂex sensitivity in the present study.
Hypoxia is known to be a stimulus ofmainly peripheral chemoreceptors,
while hypercapnia is supposed to stimulate both peripheral and central
chemoreceptors (Guyenet, 2000; Lahiri and Forster, 2003; Blain et al.,
2010). The results show that long-term (six to sevenweeks) administra-
tion of PYR was able to prevent the increased peripheral chemoreﬂex
Table 3
Cardiac function from heart failure rats and sham-operated control rats.
Control Heart failure
Water
(n = 7)
PYR
(n = 7)
Water
(n = 7)
PYR
(n = 7)
+dP/dt
(mm Hg/s)
+8811 ± 579 +8965 ± 688 +5733 ± 414⁎ +6251 ± 674⁎
−dP/dt
(mm Hg/s)
−9278 ± 349 −10,031 ± 854 −4533 ± 473⁎ −5593 ± 843⁎
LVEDP
(mm Hg)
6 ± 1 5 ± 1 13 ± 3⁎ 11 ± 2⁎
+dP/dt: maximal slope of systolic pressure increment; −dP/dt: maximal slope of
diastolic pressure decrement; LVEDP: left ventricular end-diastolic pressure;
PYR: pyridostigmine.
⁎ P b 0.05 compared to sham-operated control rats.
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sensitivity. Moreover, it is worth noting that to the best of our knowl-
edge, this is the ﬁrst study to demonstrate that HF increases central che-
moreceptor sensitivity in rats.
Aftermyocardial infarction, the heart usually adapts through a process
known as cardiac remodeling, which involves changes in the structure
and function of cardiomyocytes within the non-infarcted myocardium
that lead to cardiac hypertrophy (Murdoch et al., 2006). Additionally,
malfunctioning of the cardiac pump promotes an increase in pulmonary
capillary pressure, which undoubtedly contributes to the development0
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PYR also failed to prevent the reduction ofMAP and cardiac function
parameters (LVEDP, +dP/dt and−dP/dt) in HF rats. These results are
in agreement with previous ﬁndings from our laboratory that were
obtained six to seven weeks after coronary artery ligation in rats
(Sabino et al., 2013a). However, unpublished study from our laboratory
failed to show a decrease in MAP four weeks after coronary artery liga-
tion, and PYR improved the ejection fraction and+dP/dtmax. Therefore,
it is reasonable to hypothesize that MAP reduction is secondary to HF
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system is able to prevent the hypotension observed in rats with long-
term HF.
The higher ventilatory parameters found in rats with long-term HF
in the present study are consistent with previous observations in
patients and experimental animals with HF (Sullivan et al., 1988; Li
et al., 2006). However, other studies have shown that basal PV is
not altered in HF (Narkiewicz et al., 1999; Sun et al., 1999). Therefore,0
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imental animals remains unclear.
An increase in peripheral chemoreﬂex sensitivity has previously
been shown in patients (Chua et al., 1996; Ponikowski et al., 2001)
and in experimental models of HF (Ding et al., 2010, 2011). Moreover,
Ponikowski et al. (2001) suggested that hypersensitivity of the pe-
ripheral chemoreceptors is an independent risk factor for patients
with HF. In the present study, hypoxia induced by 15% O2 elicited sim-
ilar respiratory responses in HF rats and sham-operated control rats.
The stronger hypoxic stimulus (10% O2) revealed an increase in pe-
ripheral chemoreceptor sensitivity in HF rats. Pharmacological activa-
tion of the parasympathetic nervous system by PYR prevented the
increase in PV caused by 10% O2 hypoxia in HF rats.
In the present study, hypercapnia with either 5% CO2 or 10% CO2
promoted greater increases in RF and PV in HF rats compared to
sham-operated control rats. The TV response to higher CO2 levels
was similar among all groups. Although there is evidence of increased
central chemoreceptor sensitivity in patients (Narkiewicz et al., 1999;
Ueno et al., 2004; Yamada et al., 2004), experimental studies have
failed to demonstrate this increase in conscious HF rabbits (Sun et
al., 1999) and anesthetized HF rats (Kristen et al., 2002). The current
study is the ﬁrst to demonstrate increased central chemoreﬂex sensi-
tivity in HF rats.
PYR prevented the RF increase in HF rats but did not prevent the
PV increase. Therefore, it is reasonable to conclude that pharmacolog-
ical activation of the parasympathetic nervous system only partially
prevents the increase in central chemoreﬂex sensitivity observed inHF rats. It is worth noting that no previous studies have evaluated
both central and peripheral chemoreﬂex sensitivity in HF patients
or HF animals after pharmacological or electric activation of the para-
sympathetic nervous system.
The mechanisms behind the ﬁndings of the present study are liked
to be related to an increase in parasympathetic drive to carotid body.
Treatment with PYR is known to be able to enhance parasympathetic
activity in rats (Soares et al., 2004; Sabino et al., 2013a). An impairment
in chemoreﬂex sensitivity elicited by increased parasympathetic drive
to carotid body was demonstrated in normal animals (Fidone and
Sato, 1970). Therefore, PYR might have been able to prevent the en-
hancement in chemoreﬂex sensitivity in HF rats due to its effect on
parasympathetic activity.
In conclusion, PYR is an important pharmacological approach to
protecting physiological mechanisms during the development of HF
after coronary artery ligation. Although PYR was unable to prevent
the development of HF-related hypotension, cardiac malfunction
and increased basal PV, it was remarkably efﬁcient in preventing in-
creases in peripheral chemoreﬂex sensitivity and partially prevented
increases in central chemoreﬂex sensitivity; both of these increases
are typical outcomes of HF.Acknowledgments
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